A randomized open-label multicenter pivotal phase 2 trial (ENVASARC), to evaluate the effectiveness of envafolimab (anti-PD-L1 antibody) or envafolimab combined with ipilimumab in patients with refractory MFS and UFS, is currently ongoing. This evidence concerns the gene CD274 and Ochoa syndrome.